Rigel Pharmaceuticals, Inc. (RIGL) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance with a 76% increase in net product sales and a significant net income turnaround. The company's strategic partnerships and product demand growth, particularly for GAVRETO, are positive indicators. Despite some risks in strategic execution and global expansion, the optimistic guidance and financial discipline suggest a positive stock price movement. The market cap indicates a potential for notable reaction, but not extreme, leading to a 'Positive' sentiment.
Key Financial Performance
Net Product Sales $58.9 million, a 76% increase year-over-year. This growth was driven by a growing commercial portfolio and increased sales across all commercial products.
Total Revenue $101.7 million, including $42.7 million in contract revenues from collaborations. The increase was due to $40 million in noncash revenue recognized from the Lilly collaboration.
TAVALISSE Net Product Sales $40.1 million, a 52% increase year-over-year. Growth was driven by strong new patient demand and increased carryover demand from prior quarters.
GAVRETO Net Product Sales $11.8 million, compared to $1.9 million in Q2 2024. This represents a significant increase due to the product becoming commercially available in late June 2024 and increased new patient demand.
REZLIDHIA Net Product Sales $7 million, a 36% increase year-over-year. Growth was driven by increased demand and efforts to educate healthcare providers about its benefits.
Net Income $59.6 million, compared to a net loss of $1 million in Q2 2024. The increase was primarily due to higher revenues and the $40 million noncash revenue from the Lilly collaboration.
Cash Balance $108.4 million, compared to $77.3 million at the end of 2024. The increase was attributed to strong financial performance and revenue growth.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Net product sales: Achieved net product sales of more than $58 million in Q2 2025, a 76% year-over-year increase, driven by a growing commercial portfolio and increased sales across all commercial products.
Product-specific performance: TAVALISSE generated $40.1 million in net product sales, a 52% increase year-over-year. GAVRETO achieved $11.8 million in net product sales, reflecting a 32% sequential growth. REZLIDHIA reported $7 million in net product sales, a 36% year-over-year increase.
Pipeline development: R289, a dual IRAK1/4 inhibitor, is in Phase 1b clinical study for relapsed/refractory lower-risk MDS. Enrollment in dose escalation was completed in July 2025, with updated data expected later in the year. Olutasidenib is being explored for IDH1 mutation-positive cancers, including glioma and AML.
Global market expansion: TAVALISSE is commercially available in Japan, Europe, Canada, and Israel. It was recently launched in South Korea by JW Pharmaceutical Corporation. REZLIDHIA's market presence expanded in Asia through partnerships with Kissei and Dr. Reddy's.
Revenue growth: Total revenue for Q2 2025 was $101.7 million, including $42.7 million in contract revenues from collaborations. Revenue guidance for 2025 was raised to $270-$280 million, reflecting anticipated growth of 45%-52% compared to 2024.
Financial performance: Generated $59.6 million in net income in Q2 2025, with a cash balance of $108.4 million. Positive net income is expected for the full year 2025.
Strategic collaborations: Collaborations with CONNECT and MD Anderson to advance olutasidenib in IDH1 mutation-positive cancers. Partnership with Eli Lilly for RIPK1 inhibitor programs, with Rigel entitled to milestone and royalty payments.
In-licensing and acquisitions: Focus on acquiring or in-licensing late-stage assets in hematology and oncology to expand the product portfolio.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Product Development Risks: The company acknowledges risks and uncertainties related to regulatory and product development, which may cause actual results to differ from forecasts. This includes potential challenges in obtaining FDA approvals for new drugs or expanded indications.
Pipeline Development Risks: The development of R289 and olutasidenib involves uncertainties, including clinical trial outcomes, patient enrollment challenges, and potential delays in dose expansion studies or regulatory alignment.
Financial Risks: While the company has raised revenue guidance, there is a reliance on noncash revenue from collaborations, such as the $40 million from Lilly, which may not be sustainable. Additionally, increased R&D and personnel costs could impact profitability.
Market Competition: The company faces competitive pressures in the hematology and oncology markets, particularly for products like REZLIDHIA and GAVRETO, which require significant efforts to raise awareness and educate healthcare providers.
Supply Chain and Global Expansion Risks: Expanding access to products in international markets involves regulatory hurdles and potential delays. For example, the company is working with partners in South Korea and other regions, which may face challenges in regulatory approvals and market penetration.
Strategic Execution Risks: The company’s strategy to pursue in-licensing deals or acquisitions of late-stage assets carries risks, including the potential for overpayment, integration challenges, or failure to achieve expected synergies.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2025: Rigel has raised its total revenue guidance for 2025 to a range of $270 million to $280 million, up from the previous range of $200 million to $210 million. This includes net product sales guidance of $210 million to $220 million, an increase from the prior range of $185 million to $192 million. The updated guidance reflects anticipated growth of 45% to 52% compared to 2024.
Product Sales Growth: Net product sales for 2025 are expected to grow by 45% to 52% year-over-year, driven by increased demand and favorable market dynamics for Rigel's three commercial products: TAVALISSE, GAVRETO, and REZLIDHIA.
Pipeline Development: Rigel plans to advance its Phase 1b clinical study of R289 for lower-risk MDS, with updated data expected by year-end 2025. The dose expansion phase of the study is anticipated to begin in the second half of 2025, potentially in Q3.
Olutasidenib Expansion: Rigel intends to initiate a Phase 2 study for olutasidenib in recurrent glioma in 2025 while supporting ongoing collaborations with CONNECT and MD Anderson to explore its potential in IDH1-mutated cancers.
Strategic Collaborations and Acquisitions: Rigel remains focused on evaluating in-licensing and acquisition opportunities for late-stage assets that align with its hematology and oncology portfolio.
Financial Discipline: Rigel anticipates reporting positive net income for the full year 2025 while funding existing and new clinical development programs.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you split up the percentages contribution to the 52% growth of TAVALISSE?
A:The growth was primarily due to new patient starts, which were higher in the first half of the year. Improved patient affordability in 2025, driven by the Inflation Reduction Act, also played a significant role.
Q:What level of surprise did you have about the growth and affordability of TAVALISSE versus a potential bear case?
A:The team was prepared for the changes brought by the Inflation Reduction Act, which eliminated the coverage gap in 2025. This allowed patients easier access to TAVALISSE, and the team executed well to address this change. The growth was not entirely unexpected but benefited from improved affordability and effective execution.
Q:Is the 45%-52% growth trajectory expected to continue into 2026 and beyond?
A:Management has not provided guidance beyond this year but expects continued growth. They attribute the growth to a combination of factors, including improved affordability and a strong commercial organization. They remain optimistic about the future.
Q:What are the plans for the Phase 2 design in glioma and the CONNECT and TarGet-D trials?
A:Details about the Phase 2 design in recurrent glioma will be disclosed later this year. For the CONNECT study, discussions with CONNECT and potentially regulatory agencies are needed to determine if the data can support a filing. No additional study in the same space is anticipated.
Q:How does the IRA impact and bottle shipment numbers in 3Q shape your guidance?
A:Management expects continued growth, projecting double-digit revenue growth for the year. The IRA's impact was more significant in the first half of the year due to the elimination of the coverage gap, but its effect is expected to be less pronounced in the second half.
Q:What is the impact of the Part D changes on gross to net for the three drugs?
A:Management has not provided specific details but noted favorable gross to net dynamics due to distribution channel changes, product mix, and IRA adjustments. They expect these favorable dynamics to persist.
Q:What degree of transfusion reduction or independence is considered clinically meaningful in lower-risk MDS?
A:Current approvals for luspatercept and imetelstat are based on an 8-week transfusion independence rate of around 38%-40%. There is room for improvement, as 60% of patients do not benefit. Physicians would welcome improvements above this rate, along with better administration methods and reduced toxicities.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the gross to net impact for the three drugs and the exact design of the Phase 2 glioma study. They also did not commit to a specific growth trajectory beyond this year, using general and optimistic language instead.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CONNECT olutasidenib
Conference
Dr
Executive VP
FDA expansion
GAVRETO REZLIDHIA
GAVRETO product
GIVRETTO
IDH AML
IDH cancer
IRAK inhibitor
MDS enrollment
Phase study
REZLIDHIA IDH
REZLIDHIA Slide
REZLIDHIA product
Research Division
Rojkjaer
Slide product
VP Chief
collaboration Lilly
collaboration noncash
dose study
enrollment escalation
glioma study
imetelstat
licensing
mutation glioma
need therapy
novel IRAK
ocadusertib inhibitor
order Phase
patient ESAs
remainder
study design
track expansion
RIGL Transcript
Rigel Pharmaceuticals, Inc. (RIGL) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call highlights strong financial performance with significant year-over-year sales growth across key products, despite a slight net income decline due to higher R&D and operational expenses. The Q&A section reveals management's strategic focus on hematology/oncology, with promising developments for R289. Although some details were unclear, the overall sentiment is positive, supported by a robust revenue increase and strategic product focus. Given the company's small-cap status, the stock is likely to react positively, falling into the 2% to 8% range over the next two weeks.
Rigel Pharmaceuticals, Inc. (RIGL) Q4 2025 Earnings Call Transcript
Positive3-3
The earnings call indicates strong financial performance with significant revenue and net income growth, a raised revenue guidance for 2025, and strategic product development plans. Despite some uncertainties in global market access and management's vague responses in the Q&A, the overall sentiment is positive due to the raised guidance and strong financial metrics. The market cap suggests a moderate reaction, leading to a predicted stock price movement of 2% to 8%.
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call highlighted strong financial performance with record revenue and net income, a raised revenue guidance for 2025, and significant product sales growth. Despite some uncertainties in product development and strategic collaborations, the market reacted positively to the optimistic guidance and financial discipline. The Q&A revealed management's cautious optimism and focus on strategic growth, without major negative surprises. Given the company's small-cap status, the positive financial results and guidance are likely to drive a stock price increase in the short term.
Rigel Pharmaceuticals, Inc. (RIGL) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call reveals strong financial performance with a 76% increase in net product sales and a significant net income turnaround. The company's strategic partnerships and product demand growth, particularly for GAVRETO, are positive indicators. Despite some risks in strategic execution and global expansion, the optimistic guidance and financial discipline suggest a positive stock price movement. The market cap indicates a potential for notable reaction, but not extreme, leading to a 'Positive' sentiment.
RIGL Slides
RIGL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
